Skip to content
Screener

Arcus Biosciences RCUS Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$160.0MBeat by $127.5M
EPS-$0.08Beat by $1.06
Revenue estimate$32.5M
EPS estimate-$1.14

Next report

Oct 27, 2026 (in a month)
Revenue estimate$11.0M
EPS estimate-$0.89

Financials

Q2 2025

Income statement

See full
Revenue$160.0M+310%
Operating income-$8.0M+92.5%
Net income-+100%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$248.0M+59.0%
Total debt$109.0M+891%
Total equity$549.0M-13.5%
Total assets$1.1B-9.4%

Cash flow

See full
Operating cash flow-$133.0M-41.5%
Free cash flow-$133.0M-41.5%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$926.49M-29.4%
Enterprise value$787.49M-32.6%
P/S3.5×-1.8×

Profitability

See full
Operating margin-129%+12.4pp
Net margin-113.7%+16.7pp

Returns & leverage

See full
Return on equity-50.3%+13.7pp
Debt / equity0.2×+0.2×
Current ratio4.5×-0.6×

Segments

By segment

See full
Reportable segment$160.0M+310%

By product

See full
R&D services$2.0M—

FAQ

When did Arcus Biosciences report Q2 2025 earnings?
Arcus Biosciences (RCUS) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Arcus Biosciences's Q2 2025 revenue and EPS?
Arcus Biosciences reported revenue of $160.0M and eps of $-0.08 for Q2 2025.
Did Arcus Biosciences beat estimates in Q2 2025?
Revenue beat the consensus estimate of $32.5M by $127.5M. EPS beat the consensus estimate of $-1.14 by $1.06.
How did Arcus Biosciences's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 310.3% from $39.0M a year earlier and eps grew 92.6% from $-1.02.
Where can I find Arcus Biosciences's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001724521-25-000099) and the 10-Q periodic report (0001724521-25-000101) directly on SEC EDGAR. The filing index links above go to sec.gov.